

Date: 5<sup>th</sup> April, 2024

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code:533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned matter, we wish to inform you that Alembic Global Holding SA, wholly owned subsidiary of Alembic Pharmaceuticals Limited ("Company") has subscribed in a new entity named TicTwo Therapeutics Inc.

The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid acquisition is enclosed as Annexure – I.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**

**Manisha Saraf**  
**Company Secretary**  
Encl: A/a

**ALEMBIC PHARMACEUTICALS LIMITED**

## Annexure-I

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as specified in Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:

Sr. No.	Particulars	
i)	Name of the target entity, details in brief such as size, turnover etc	TicTwo Therapeutics Inc. ("TicTwo") is a company incorporated in the State of Delaware on 29 <sup>th</sup> February, 2024.
ii)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The proposed acquisition of TicTwo (Being a step-down subsidiary acquired by wholly owned subsidiary i.e. Alembic Global Holding SA) does not fall under related party transaction.  The promoter / promoter/ promoter group are not interested in the transaction.
iii)	Industry to which the entity being acquired belongs	Pharmaceuticals
iv)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable
v)	Brief details of any governmental or regulatory approvals required for the acquisition	No
vi)	Indicative time period for completion of the acquisition	3 Months

### **ALEMBIC PHARMACEUTICALS LIMITED**

vii)	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
viii)	Cost of acquisition and/or the price at which the shares are acquired;	\$600
ix)	Percentage of shareholding / control acquired and / or number of shares acquired	Alembic Global Holding SA will own 93% equity interest of TicTwo Therapeutics Inc. The Company holds 100% in Alembic Global Holding SA.
x)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Not applicable, as this intimation is about a newly incorporated entity.

## **ALEMBIC PHARMACEUTICALS LIMITED**